Company Filing History:
Years Active: 2019
Title: Jefferson Revell: Innovator in Protease-Resistant Peptides
Introduction
Jefferson Revell is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of biochemistry, particularly in the development of protease-resistant peptides. His innovative work has led to advancements in therapeutic applications, showcasing his expertise and dedication to scientific research.
Latest Patents
Revell holds a patent for "Protease-resistant lipidated GLP-1 analogs." This invention provides protease-resistant peptides, methods for making such peptides, and compositions that include these peptides. The patent outlines a method of treatment utilizing these peptides, which are produced through a combination of lipidation of specific amino acid residues and the substitution of alpha-methyl functionalized amino acids for natural amino acids. This innovative approach has the potential to enhance the efficacy of peptide-based therapies.
Career Highlights
Jefferson Revell is currently associated with Medimmune Limited, where he continues to work on groundbreaking research in the field of biopharmaceuticals. His role at the company allows him to collaborate with other experts and contribute to the development of novel therapeutic solutions.
Collaborations
Revell has worked alongside Maria Aleksandra Bednarek, a fellow researcher, to advance their shared goals in the field of peptide research. Their collaboration exemplifies the importance of teamwork in driving innovation and achieving scientific breakthroughs.
Conclusion
Jefferson Revell's contributions to the field of protease-resistant peptides highlight his role as an influential inventor. His patent and ongoing work at Medimmune Limited demonstrate his commitment to advancing biopharmaceutical research.